Datasheet for ABIN1714777

anti-FUNDC1 antibody (AA 51-150)

Go to Product page

1 Image

Overview

Quantity:	100 µL
Target:	FUNDC1
Binding Specificity:	AA 51-150
Reactivity:	Human, Mouse, Rat
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This FUNDC1 antibody is un-conjugated
Application:	Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunocytochemistry (ICC)

Product Details

Immunogen:	KLH conjugated synthetic peptide derived from human FUNDC1
Isotype:	IgG
Cross-Reactivity:	Human, Mouse, Rat
Predicted Reactivity:	Dog,Cow,Sheep,Pig,Horse
Purification:	Purified by Protein A.

Target Details

Target:	FUNDC1

 Copyright antibodies-online. All rights reserved.

Target Details

Alternative Name:	Fundc1 (FUNDC1 Products)
Background:	Synonyms: FUN14 domain containing protein 1, FUN14 domain-containing protein 1, FUND1_HUMAN. Background: FUNDC1 is a 155 amino acid protein belonging to the FUN14 family. The gene encoding FUNDC1 maps to human chromosome Xp11.3 and mouse chromosome X A1.2. The X and Y chromosomes are the human sex chromosomes. Chromosome X consists of about 153 million base pairs and nearly 1,000 genes. The combination of an X and Y chromosome lead to normal male development while two copies of X lead to normal female development. More than one copy of the X chromosome with a Y chromosome causes Klinefelter's syndrome. A single copy of X alone leads to Turner's syndrome. More than 2 copies of the X chromosome, in the absence of a Y chromosome, is known as Triple X syndrome. Color blindness, hemophilia, and Duchenne muscular dystrophy are well known X chromosome-linked conditions which affect males more frequently as males carry a single X chromosome.
Gene ID:	139341

Application Details

Application Notes:	WB 1:300-5000
	ELISA 1:500-1000
	IHC-P 1:200-400
	IHC-F 1:100-500
	IF(IHC-P) 1:50-200
	IF(IHC-F) 1:50-200
	IF(ICC) 1:50-200
	ICC 1:100-500

Restrictions:	For Research Use only

Handling

Format:	Liquid
Concentration:	1 µg/µL
Buffer:	0.01M TBS(pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
Preservative:	ProClin
Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be

Handling

	handled by trained staff only.
Storage:	4 °C,-20 °C
Storage Comment:	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Expiry Date:	12 months

Images



Western Blotting

Image 1. DrFundc1 reduced cell viability while inducing autophagy and apoptosis in transgenic 293T cells. (A) Western blotting of proteins extracted from mitochondria and cytoplasm from transgenic 293T cells transfected with pCS2+-Drfundc1-Cherry-His as well as pCS2+-Cherry plasmids. Antibodies used were anti-Cherry (detecting Drfundc1-Cherry-His and Cherry), anti-FUNDC1, anti-COX IV, anti-LC3B, and anti-β-ACTIN. (A1) Results of Western blotting. (A2) Gray-scale analyses of DrFundc1 using ImageJ in mitochondria and cytoplasm of cells transfected with pCS2+-Drfundc1-Cherry-His. (A3) LC3B-II:LC3B-I ratio in mitochondria of transgenic cells transfected with pCS2+-Drfundc1-Cherry-His and pCS2+-Cherry. (B) DrFundc1 decreased viability of 293T cells, measured by MTT assay. (C-D) DrFundc1 increased 293T cell mortality, measured by Trypan Blue staining. (E) DrFundc1 decreased cell proliferation in transgenic cells, detected using BrdU incorporation. (F) DrFundc1 led to apoptosis of 293T cells, detected using TUNEL assay. Arrows show apoptotic cells. Red indicates DrFundc1-Cherry or Cherry, while green indicates TUNEL-positive cells. Positive control: Cherry+DNase I. Negative control: incubation without TdT enzyme. (G) Expressional fold change of autophagy- and apoptosis-related genes, detected using qRT-PCR. β-ACTIN was used as an internal control. Significant differences between cells transfected with different plasmids are shown

as asterisks. *P<0.05, **P<0.01, ***P<0.001. - figure provided by CiteAb. Source: PMID31827208

 Copyright antibodies-online. All rights reserved.